Reaction
Precancerous Condition reporting signals
As of the last recalculation, Precancerous Condition appears in 646 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is ACALABRUTINIB (PRR 29.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Acalabrutinib | 11 | 29.7 | 29.8 |
| Azelastine | 16 | 29.4 | 29.4 |
| Risankizumab-Rzaa | 64 | 27.9 | 27.9 |
| Fluticasone Furoate And Vilanterol Trifenatate | 27 | 25.2 | 25.2 |
| Mepolizumab | 29 | 19.6 | 19.7 |
| Naproxen Sodium Tablet, Coated | 8 | 19.3 | 19.3 |
| Naproxen Sodium, Coated Tablets | 8 | 19.3 | 19.3 |
| Naproxen Sodium 220Mg | 8 | 19.2 | 19.2 |
| Upadacitinib | 31 | 12.8 | 12.8 |
| Ruxolitinib | 26 | 12.1 | 12.1 |
| Ranitidine Hydrochloride | 12 | 7.2 | 7.2 |